Publications by authors named "M W Krucoff"
Glioblastoma is the most common primary brain tumor in adult patients, and despite standard-of-care treatment, median survival has remained less than two years. Advances in our understanding of molecular mutations have led to changes in the diagnostic criteria of glioblastoma, with the WHO classification integrating important mutations into the grading system in 2021. We sought to review the basics of the important genetic mutations associated with glioblastoma, including known mechanisms and roles in disease pathogenesis/treatment.
View Article and Find Full Text PDFBackground: Accurate bleeding risk stratification after percutaneous coronary intervention (PCI) is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of high bleeding risk patients. We derived and validated a novel bleeding risk score by augmenting the PRECISE-DAPT score with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria.
View Article and Find Full Text PDFImpact of ticagrelor with or without aspirin on total and recurrent bleeding and ischemic events after percutaneous coronary intervention: A sub-study of the TWILIGHT trial.
Eur Heart J Cardiovasc Pharmacother
October 2024
Article Synopsis
- The study evaluates the impact of early discontinuation of aspirin in favor of ticagrelor monotherapy on bleeding and ischemic events in patients who underwent percutaneous coronary intervention (PCI).
- Results show that while ticagrelor monotherapy led to significantly fewer bleeding events compared to ticagrelor plus aspirin, the total ischemic events remained similar between the two groups.
- Overall, among high-risk PCI patients, ticagrelor alone was associated with reduced bleeding without increasing the risk of ischemic complications.
Article Synopsis
- Glioblastoma multiforme (GBM) is the most aggressive brain tumor but rarely spreads outside the central nervous system, with only 0.4% of cases showing metastasis, possibly influenced by genetic mutations.
- A systematic review analyzed 357 studies and 211 patients, revealing that 36.9% of metastases were found near surgical sites and common metastasis locations included bone, lung, and lymph nodes.
- Unique genetic mutations were observed in primary GBM and metastatic lesions, suggesting that understanding these changes could explain how GBMs spread beyond the CNS and aid future treatment strategies.
Article Synopsis
- In 2019, the FDA warned that devices coated with paclitaxel for treating claudication might be linked to higher mortality rates over five years, prompting a study to explore patient preferences between risks of revascularization and mortality.
- A survey involving 272 patients from seven medical centers used discrete-choice experiments to assess how much increased mortality risk they would accept in exchange for decreased chances of needing further procedures on their blood vessels.
- Results indicated that patients would generally tolerate a small increase in 5-year mortality risk (up to 12.6%) to achieve significant reductions in treatment risks, though there was notable variability in individual risk tolerance, highlighting the need for tailored decision-making support.